Deutsche Post AG

  • WKN: 555200
  • ISIN: DE0005552004
  • Land: Germany

Nachricht vom 08.10.2021 | 09:33

Deutsche Post AG: Release of a capital market information

Deutsche Post AG / Announcement pursuant to section 5 para 3 of Regulation (EU) No. 596/2014 in conjunction with section 2 para 2 and 3 of the delegated regulation (EU) 2016/1052 of the commission
08.10.2021 / 09:33
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Announcement pursuant to section 5 para 3 of Regulation (EU) No. 596/2014 in conjunction with section 2 para 2 and 3 of the delegated regulation (EU) 2016/1052 of the commission

Information on share buyback program
08. October 2021

Deutsche Post AG, Bonn, Germany
WKN: 555200
ISIN: DE0005552004

In the time period from 04 October 2021 until and including 06 October 2021, a number of 1,649,653 shares were bought back via XETRA within the framework of the current share buyback program of Deutsche Post AG.

Shares were bought back as follows:

Date Number of shares acquired Average price (€) Purchased volume (€)
04 Oct 2021 743,055 53.9632 40,097,625.58
05 Oct 2021 500,153 53.7314 26,873,920.90
06 Oct 2021 406,445 53.1962 21,621,329.51
       
       
       
       
Total 1,649,653 53.7039 88,592,875.99
 

An overview of the underlying individual trades is published on the company website (https://www.dpdhl.com/en/investors/shares/share-buy-backs.html).

The total volume of shares which have been bought back within the framework of the current share buyback program in the time period from 10 May 2021 until and including 06 October 2021 amounts to 17,694,910 shares.

Contact:

Martin Ziegenbalg
EVP Investor Relations
Tel. +49 (0) 228 63000

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.



08.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021